MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Spero Therapeutics, Inc. (NASDAQ: SPRO)*
Organization & Developments: Spero Therapeutics
Parents
Spero Therapeutics, Inc. (NASDAQ: SPRO)*
Children
*Antibiotic startup, is working on novel mechanisms of addressing Gram negative infections
2018: Our First Look At Spero Therapeutics_seekingalpha.com
2021: Sizing Up Spero Therapeutic
2022: GSK plays the white knight, paying $66M to rescue Spero's oral antibiotic after FDA rejection
2024: Spero speared by antibiotic flop, triggering 39% workforce cut
2025: Spero surges as GSK-partnered UTI candidate succeeds in late-stage trial
2025: Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results
2025: Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal_ seekingalpha.com
Jumps
Finance & Acquisitions: Spero Therapeutics
Key People: Spero Therapeutics